Clinical trial · Interventional
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. These low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment. A tracer is an extremely small quantity of a substance. Tracer to which radioactivity has been attached may be used to "trace" events in the body. A tracer called iodo-azomycin galactopyranoside (or \*IAZGP) appears to be able to detect low oxygen areas within tumor. Radioactive iodine in this molecule can be detected by an imaging technique called a PET scan. This present study involves obtaining three scans using this new imaging technique. The goal of carrying out many scans is to determine which scan will best show any areas in your tumor that may have low levels of oxygen.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| CERVIX UTERI NOS | — | UNRESOLVED | — |
| HEENT Cancer | — | UNRESOLVED | — |
| RECTUM | — | UNRESOLVED | — |
| Renal Cancer | — | UNRESOLVED | — |
| Uterine Cancer | Malignant Uterine Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 124I-Iodo-Azomycin Galacto-Pyranoside | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Patients will receive 124IAZGP(124I-Iodo-Azomycin Galacto-Pyranoside).
- interventionNames
- Radiation: 124I-Iodo-Azomycin Galacto-Pyranoside
Primary outcomes (3)
- measure
- To describe imaging findings in human cancer with the new hypoxia tracer 124IAZGP and PET/CT
- timeFrame
- at least once at approximately 6 hours and/or 24 hours after radiotracer administration.
- measure
- To evaluate the biodistribution of 124IAZGP using serial PET imaging and to estimate blood radioactivity
- timeFrame
- 5, 15, 30 and 60 minutes after 124IAZGP, and before and after each. A 5-mL volume of blood will be drawn at each sampling time point.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have locally advanced cancer as determined by currently accepted diagnostic work-up, including CT/MR/US. * KPS \>70%. * Patients must be \> or equal to 18 years of age. Exclusion Criteria: * Patients will be excluded from the study if they fulfill any of the following criteria: * Patients with abnormal baseline thyroid function tests, or any thyroid disorder including but not limited to hypothyroidism and thyroiditis. Patients with thyroid cancer who have had a thyroidectomy are not excluded. * Patients who are pregnant or lactating. * Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study. * Patients who cannot tolerate being in the PET scanner for the duration of the study.
References
Publications (1)
- DERIVEDO'Donoghue JA, Guillem JG, Schoder H, Lee NY, Divgi CR, Ruby JA, Humm JL, Lee-Kong SA, Burnazi EM, Cai S, Carlin SD, Leibold T, Zanzonico PB, Ling CC. Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer. EJNMMI Res. 2013 Jun 3;3(1):42. doi: 10.1186/2191-219X-3-42. PMID 23731770